ArcDia / mariPOC
ArcDia develops what it claims to be the most complete in vitro diagnostic solutions for acute infections suitable for decentralized testing of respiratory and gastrointestinal infections such as COVID-19, influenza, RSV, CDI and many more. It provides hospitals, healthcare centers, transportation hubs and workplaces with high-quality tests that are fast, high-throughput and reliable. The company's mariPOC platform is designed for detecting acute and contagious infections, using the sandwich immunoassay principle and two-photon excited fluorescence assay technique — enabling automation, ease-of-use, multianalyte capability, cost-efficiency and high performance.
Select investors Lifeline Ventures, Finnvera, Innovestor
Key people 🧑🤝🧑
- Solving the problem: Antibiotic resistance is a growing concern globally, with resistance being responsible for causing 23,000 deaths per year in the US alone. ArcDia's pipeline product portfolio includes mariAST (RUO), a solution for tackling antibiotic resistance by speeding up antimicrobial susceptibility testing.
- Real-time epidemiological surveillance: ArcDia's mariCloud is an online service for real-time epidemiological surveillance. The tool helps healthcare professionals monitor infection incidence in real time and enables improved pandemic and epidemic preparedness.
- Available worldwide: As of May 2023, mariPOC diagnostic solutions were available in more than 30 countries. 🔗
Awards & Recognitions 🏆
- 2014 Frost & Sullivan Award for Point-of-Care Product Leadership 🔗
Last update: May 23, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more